PHASE Scientific Completes Series A Financing to Advance Urine-Based Diagnostics
Hong Kong-based urine-based diagnostics specialist PHASE Scientific International Limited announced the completion of a Series...
Finance
Shanghai CureGene Completes Series B+ Financing to Advance CG-0255 Study
China-based Shanghai CureGene Pharmaceutical Co., Ltd announced the completion of a Series B+ financing round,...
Accurate Biotechnology Secures RMB 100M in Series B Funding for Organoid Technology
Accurate Biotechnology, a Guangzhou-based biotech focused on organoid technology, reportedly raised RMB 100 million (USD...
Sanofi Announces $20 Billion Investment in US R&D and Manufacturing by 2030
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its intention to invest at least $20...
Acchrom Technologies Secures Pre-Series B Funding to Expand Chromatography Solutions
Beijing-based Acchrom Technologies Co., Ltd., a specialist in chromatography, has reportedly secured over RMB 100...
OYMotion Technologies Secures RMB 100 Million in Series B++ Funding for Exoskeleton Robots
Shanghai-based OYMotion Technologies Co., Ltd, a high-tech company specializing in brain-computer interface and robotics technology,...
EnChannel Medical Secures RMB 600 Million in Series B Funding for Electrophysiological Products
China-based EnChannel Medical Guangzhou Inc., a specialist in electrophysiology, has reportedly secured RMB 600 million...
Sanyou Medical Partners with CGBio to Launch Regenerative Medicine Joint Venture
China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced plans to establish a joint venture...
Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing
China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...
EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology
EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series...
AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...
Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...
BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...
Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China
Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...
Chipscreen Biosciences Cuts Private Placement Proceeds to RMB 950 Million
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has revised its private placement proceeds to RMB...
LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline
Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round...
Sanofi Reports Q1 Sales Growth Driven by Dupixent and New Product Launches
French pharmaceutical giant Sanofi (NASDAQ: SNY) released its Q1 2025 financial results, reporting global net...
Shineco Inc. Announces Acquisition of InfiniClone for Regenerative Medicine Expansion
US-based Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Shineco Life Sciences Group Hong Kong...
Shenzhen Core Medical Closes Series D Round to Advance Miniaturized Artificial Hearts
Shenzhen Core Medical Technology Co., Ltd, a developer of mechanical circulation assist systems, has reportedly...
Hotgen Biotech Injects RMB 300 Million into Subsidiary Sungen Bio for Biologic R&D
China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic capital injection plan, partnering...